
Clene Inc. CLNN.O:
CLENE PROVIDES REGULATORY UPDATE FOLLOWING CONSTRUCTIVE FDA TYPE-C MEETING ON NEUROFILAMENT BIOMARKER ANALYSIS PLAN AND CONFIRMS TWO ADDITIONAL FDA MEETINGS
CLENE INC. - CONFIRMS TWO ADDITIONAL FDA MEETINGS FOR Q3 2025
CLENE INC. - ON TRACK FOR ALS NDA SUBMISSION IN Q4 2025
CLENE INC. - NFL EAP BIOMARKER ANALYSES TO BE CONDUCTED EARLY Q4 2025
CLENE INC. - FDA PROVIDES SUPPORTIVE FEEDBACK ON CLENE'S BIOMARKER ANALYSIS PLAN